PI11314 Trityl candesartan cilexetil (CAS No.: 170791-09-0)

Trityl candesartan cilexetil (CAS No.: 170791-09-0) Description

Trityl candesartan cilexetil, formulated as a powder with the chemical composition C52H48N6O6, serves as an intermediate in the synthesis of candesartan cilexetil-based drugs. The compound is produced under strictly controlled conditions to ensure reproducibility and minimise impurities. Verification through HPLC and NMR underpins its precise molecular composition, making it suitable for formulation processes that require accurate stoichiometric balance.

Trityl candesartan cilexetil (CAS No.: 170791-09-0) Applications

1.         Pharmaceutical Manufacturing
   - Used as an intermediate in candesartan drug formulations to achieve high conversion efficiency by leveraging its defined chemical structure.
   - Applied as a reactive building block in synthetic routes to facilitate optimised process yields, ensuring consistent functioning in production batches.

2.         Process Development
   - Employed as a model compound in reaction optimisation studies to achieve scalable synthesis while minimising impurity profiles by utilising its high reactivity.
   - Utilised in pilot-scale studies to validate reproducibility and performance under controlled processing conditions, thereby supporting method development.

Trityl candesartan cilexetil (CAS No.: 170791-09-0) Packing

Trityl candesartan cilexetil is packaged in sealed, inert containers with an internal moisture barrier to prevent contamination. The powder is securely held in anti-static materials and stored under temperature-controlled conditions. This protective packaging minimises exposure to environmental factors and physical degradation. Custom labelling and compartmentalised packaging options are available to support batch traceability and specific storage requirements.

Additional Information

Pharmaceutical intermediates such as Trityl candesartan cilexetil play a critical role in the multi-step synthesis of active drug compounds. Their controlled production and rigorous quality evaluation ensure that final formulations achieve the necessary therapeutic standards. The chemical uniformity and purity attained through systematic process control are essential for maintaining consistency during scale-up operations.

Understanding the broader context of pharmaceutical synthesis reveals that intermediates require precise control during production to mitigate process variability. The integration of advanced analytical techniques in production helps bridge the gap between laboratory-scale synthesis and industrial manufacturing, ensuring that subsequent formulation processes yield effective and reproducible therapeutic products.